Invivyd grants 1,125,000 options to CMO Michael

Invivyd, Inc. granted Chief Medical Officer and Chief Epidemiologist Michael Mina a stock option for 1,125,000 shares of common stock, with an exercise price of $0.535 per share and expiration on July 30, 2036.

Rhea-AI Filing Summary

Invivyd, Inc. granted Chief Medical Officer and Chief Epidemiologist Michael Mina a stock option for 1,125,000 shares of common stock, with an exercise price of $0.535 per share and expiration on July 30, 2036. The option vests over four years: 25% on July 31, 2027, and the remaining 75% in substantially equal monthly installments (1/48 of the total) over the following three years, subject to his continuous service.

Insider Trade Summary

Grant/Award: 1,125,000 shares

Grant/Award 1 txn

Insider Mina Michael

Role CMO and Chief Epidemiologist

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	1,125,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,125,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of July 31, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.

Key Figures

Options Granted: 1,125,000 options Exercise Price: $0.535 per share Expiration Date: July 30, 2036 +3 more

6 metrics

Options Granted 1,125,000 options Stock option grant to Michael Mina on 2026-07-31

Exercise Price $0.535 per share Exercise price of stock options for Invivyd common stock

Expiration Date July 30, 2036 Expiration of stock option grant to Michael Mina

Post-transaction Holdings 1,125,000 derivative securities Total stock options held after the reported grant

Initial Vesting Tranche 25% on July 31, 2027 First anniversary of July 31, 2026 grant date

Monthly Vesting Rate 1/48 of total shares per month Remaining 75% of options vesting over three years

Key Terms

Stock Option (Right to Buy), Common Stock, vesting, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"This option vests over a four-year period, with 25% of the shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service other

"subject to the Reporting Person's continuous service as of each vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Invivyd (IVVD) report for Michael Mina in this Form 4?

Invivyd reported a grant of 1,125,000 stock options to Chief Medical Officer and Chief Epidemiologist Michael Mina, each with an exercise price of $0.535 per share, expiring on July 30, 2036, as disclosed in the Form 4.

What is the exercise price of the stock options granted to Invivyd (IVVD) CMO Michael Mina?

The stock options granted to Michael Mina carry an exercise price of $0.535 per share. These options relate to 1,125,000 underlying shares of Invivyd common stock and expire on July 30, 2036, according to the Form 4 disclosure.

How do the Invivyd (IVVD) stock options granted to Michael Mina vest?

The option vests over four years: 25% of the shares vest on the first anniversary of the July 31, 2026 grant date, and the remaining 75% vest in substantially equal monthly installments of 1/48 of the total, subject to continuous service.

When do the stock options for Invivyd (IVVD) CMO Michael Mina expire?

The stock options granted to Michael Mina expire on July 30, 2036. He was granted options covering 1,125,000 shares of Invivyd common stock, with vesting over four years and an exercise price of $0.535 per share.

Are Michael Mina’s Invivyd (IVVD) option grants under a Rule 10b5-1 trading plan?

The Form 4 indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan. The Rule 10b5-1 checkbox is explicitly unchecked, so the option grant is not reported as pre-arranged under such a plan.

How many Invivyd (IVVD) derivative securities does Michael Mina hold after this transaction?

Following the grant, Michael Mina holds 1,125,000 derivative securities in the form of stock options. These options are directly owned and correspond to the right to acquire 1,125,000 shares of Invivyd common stock, subject to the vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 04:15 PM Accepted by SEC EDGAR 08/04/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mina Michael

(Last) (First) (Middle)

C/O INVIVYD, INC.

209 CHURCH STREET

(Street)

NEW HAVEN CONNECTICUT 06510

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Invivyd, Inc. [ IVVD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO and Chief Epidemiologist

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.535	07/31/2026		A		1,125,000		(1)	07/30/2036	Common Stock	1,125,000	$0	1,125,000	D

Explanation of Responses:

1. This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of July 31, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.

	/s/ Jill Andersen attorney-in-fact for Michael Mina	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)